Demographic and transplant-related characteristics of the study cohort
Parameter . | All (n = 54) . |
---|---|
Recipient age at HSCT, y (median, IQR) | 57 (62) |
Recipient genre (M:F) | 37:17 |
Donor age, y (median, IQR) | 41 (21.5) |
Donor genre (M:F) | 39:15 |
Underlying diagnosis, n (%) | |
AML | 27 (50) |
ALL | 4 (7.4) |
AL nonspecific | 2 (3.7) |
CML/CLL | 2 (3.7) |
Lymphoma | 4 (7.5) |
Myeloma | 1 (1.9) |
MDPS/MDS/MPS | 12 (22.2) |
Hemoglobinopathy | 2 (3.7) |
Donor type, n (%) | |
MUD | 22 (40.7) |
MMUD | 2 (3.7) |
MRD | 9 (16.7) |
Haploidentical | 21 (38.9) |
First transplantation, n (%) | 49 (90.7) |
Conditioning with ATG, n (%) | 39 (72.2) |
PTCy, n (%) | 22 (40.7) |
No T-cell depletion, n (%) | 53 (98.1) |
Cryopreservation, n (%) | 43 (79.6) |
Stem cell source, n (%) | |
BM | 3 (5.5) |
PBSC | 51 (94.4) |
CMV serostatus, n (%) | |
D+/R+ | 22 (40.7) |
D–/R+ | 12 (22.2) |
D+/R– | 7 (13) |
D–/R– | 13 (24.1) |
Disease risk index, n (%) | |
Low | 4 (7.4) |
Intermediate | 41 (75.9) |
High/very high | 7 (13) |
NA | 2 (3.7) |
Parameter . | All (n = 54) . |
---|---|
Recipient age at HSCT, y (median, IQR) | 57 (62) |
Recipient genre (M:F) | 37:17 |
Donor age, y (median, IQR) | 41 (21.5) |
Donor genre (M:F) | 39:15 |
Underlying diagnosis, n (%) | |
AML | 27 (50) |
ALL | 4 (7.4) |
AL nonspecific | 2 (3.7) |
CML/CLL | 2 (3.7) |
Lymphoma | 4 (7.5) |
Myeloma | 1 (1.9) |
MDPS/MDS/MPS | 12 (22.2) |
Hemoglobinopathy | 2 (3.7) |
Donor type, n (%) | |
MUD | 22 (40.7) |
MMUD | 2 (3.7) |
MRD | 9 (16.7) |
Haploidentical | 21 (38.9) |
First transplantation, n (%) | 49 (90.7) |
Conditioning with ATG, n (%) | 39 (72.2) |
PTCy, n (%) | 22 (40.7) |
No T-cell depletion, n (%) | 53 (98.1) |
Cryopreservation, n (%) | 43 (79.6) |
Stem cell source, n (%) | |
BM | 3 (5.5) |
PBSC | 51 (94.4) |
CMV serostatus, n (%) | |
D+/R+ | 22 (40.7) |
D–/R+ | 12 (22.2) |
D+/R– | 7 (13) |
D–/R– | 13 (24.1) |
Disease risk index, n (%) | |
Low | 4 (7.4) |
Intermediate | 41 (75.9) |
High/very high | 7 (13) |
NA | 2 (3.7) |
AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; MDPS, myelodysplastic/myeloproliferative syndrome; MDS, myelodysplastic syndrome; MMUD, mismatched unrelated donor; MPS, myeloproliferative syndrome; MRD, matched related donor; MUD, matched unrelated donor; PBSC, peripheral blood stem cells; PTCy, posttransplant cyclophosphamide.